Carmustine clinical trials
Also written BCNU, BiCNU and FDA 0345.
Counted the way a researcher would: Carmustine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Carmustine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Carmustine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Mar 1977 · BICNU · NDA 017422 (FDA, Drugs@FDA)
- European Union
- 18 Jul 2018 · Carmustine medac (previously Carmustine Obvius) · EMEA/H/C/004326 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
83 studies that test it; most in 2000 (10)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1994 | 1 |
| 1995 | 3 |
| 1996 | 4 |
| 1997 | 2 |
| 1998 | 9 |
| 1999 | 6 |
| 2000 | 10 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 80
Fred Hutchinson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (6) · City of Hope Medical Center (6) · Duke University (6) · National Cancer Institute (NCI) (5) · Radiation Therapy Oncology Group (4) · Washington University School of Medicine (4) · Alliance for Clinical Trials in Oncology (3)
Often tested with
Tested in the same studies.
Etoposide (40) · Cytarabine (31) · Melphalan (29) · Cyclophosphamide (22) · O(6)-benzylguanine (13) · Temozolomide (7) · Filgrastim (6) · Rituximab (4)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Carmustine is the comparator. A study of two new drugs counts under both.
- 1Tucidinostat · Sichuan University
Reaching primary completion within a year · 4
Studies that test Carmustine.
- Jan 2027Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver MetastasesPhase 2 · Thomas Jefferson University
- Apr 2027High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaPhase 1 · Memorial Sloan Kettering Cancer Center
- Sep 2027Auto Stem Cell Transplant for Lymphoma PatientsPhase 2 · Masonic Cancer Center, University of Minnesota
- Oct 2027Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Phase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses Carmustine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 85
- Auto Stem Cell Transplant for Lymphoma PatientsRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03125642Written as BCNU
- Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)RecruitingPhase 1Washington University School of MedicineNCT05521984Written as Carmustine
- A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain DiseaseRecruitingPhase 2University of NebraskaNCT04222062Written as Carmustine 7.7Mg Wafer
- Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04871607Written as Carmustine
- Modified BEAM Regimen for T Cell Lymphoma Underwent ASCTNot yet recruitingNot applicableFirst Affiliated Hospital Xi'an Jiaotong UniversityNCT05814718Written as modified BEAM
- Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02570542Written as carmustine, etoposide, cytarabine, melphalan
- Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT01511562Written as carmustine
- High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT01840566Written as Carmustine
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantActive, not recruitingPhase 1/2AIDS Malignancy ConsortiumNCT02797470Written as Carmustine
- Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular AnalysisCompletedPhase 2Assistance Publique Hopitaux De MarseilleNCT04755023Written as Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
- Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver MetastasesActive, not recruitingPhase 2Thomas Jefferson UniversityNCT04728633Written as Carmustine
- Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedPhase 1City of Hope Medical CenterNCT00641381Written as carmustine
- Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesActive, not recruitingPhase 2Fred Hutchinson Cancer CenterNCT00716066Written as Carmustine
- Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaCompletedPhase 1/2Ohio State University Comprehensive Cancer CenterNCT03583424Written as Carmustine
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedPhase 1City of Hope Medical CenterNCT02342782Written as Carmustine
- A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaTerminatedPhase 1/2Karyopharm Therapeutics IncNCT04421378Written as Carmustine
- Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's LymphomaCompletedPhase 2University of NebraskaNCT00080886Written as carmustine
- LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins LymphomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00610883Written as LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
- Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's LymphomaCompletedPhase 2University of NebraskaNCT00006695Written as carmustine
- Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnPhase 1Fred Hutchinson Cancer CenterNCT05228249Written as Carmustine
See all 85 studies that test Carmustine →
Given beside what is tested · 61 — Carmustine is usual care or a partner of the new treatment
- MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06377540Written as Carmustine
- hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)RecruitingPhase 2Leland MethenyNCT05052957Written as carmustine
- CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantRecruitingPhase 2Washington University School of MedicineNCT06687772Written as Carmustine
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsRecruitingPhase 1General Oncology, Inc.NCT04150042Written as BCNU
- Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNot applicableRuijin HospitalNCT05863845Written as Carmustine
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02443077Written as Carmustine
- Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin LymphomaCompletedPhase 1City of Hope Medical CenterNCT01476839Written as carmustine
- Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnPhase 2Eric Jacobsen, MDNCT06692452Written as Carmustine
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) LymphomaCompletedPhase 2International Extranodal Lymphoma Study Group (IELSG)NCT01011920Written as BCNU
- Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven MaintenanceCompletedPhase 2The Lymphoma Academic Research OrganisationNCT02896582Written as Carmustine
- New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System InvolvementCompletedPhase 2International Extranodal Lymphoma Study Group (IELSG)NCT02329080Written as Carmustine
- CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid MalignanciesCompletedPhase 1M.D. Anderson Cancer CenterNCT00968760Written as Carmustine
- Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedPhase 1Washington University School of MedicineNCT03072771Written as Carmustine
- Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin LymphomaCompletedPhase 1/2University of NebraskaNCT01035463Written as Carmustine
- Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedPhase 2University of NebraskaNCT00007852Written as carmustine
- Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT03019640Written as Carmustine
- Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLStatus unknownPhase 2Swedish Medical CenterNCT03736616Written as Carmustine
- O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant GliomasTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT00669669Written as Carmustine
- Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCTCompletedPhase 2Stanford UniversityNCT00350181Written as BCNU
- Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory LymphomaCompletedPhase 1/2Weill Medical College of Cornell UniversityNCT02059239Written as Carmustine
Showing 20 of 61.
As the comparator · 6 — what is tested is compared with Carmustine
- Tebentafusp-tebn With LDT in Metastatic UMRecruitingPhase 1/2Thomas Jefferson UniversityNCT06626516Written as BCNU
- A Study of Carmustine With and Without Ethanol in Subjects With LymphomaRecruitingPhase 2VIVUS LLCNCT06915246Written as BiCNU
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as Carmustine
- Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM SubjectsTerminatedPhase 1/2VBI Vaccines Inc.NCT03382977Written as Carmustine
- Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary GlioblastomaTerminatedPhase 3Isarna Therapeutics GmbHNCT00761280Written as carmustine
- Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCLStatus unknownPhase 3European Mantle Cell Lymphoma NetworkNCT00209222Written as BCNU
Codes
What other systems call Carmustine · ClinicalTrials.gg INT007154
- MeSH (NLM) D002330CarmustineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) U68WG3173YCARMUSTINEConfirmed FDA, NLM, Wikidata
- RxNorm 2105Confirmed FDA, Wikidata
- Wikidata Q415869carmustineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C349CarmustineOne source FDA
- DrugBank DB00262One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002330 | Carmustine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | U68WG3173Y | CARMUSTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2105 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415869 | carmustine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C349 | Carmustine | One source FDA |
| DrugBank | DB00262 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.